1st Department of Anesthesiology and Intensive Care, Medical University of Warsaw, Warsaw, Poland.
Medicine (Baltimore). 2023 Mar 10;102(10):e33238. doi: 10.1097/MD.0000000000033238.
Malignant hyperthermia (MH) is a life-threatening syndrome caused by sudden, uncontrolled skeletal muscle hypermetabolism in response to inhalation anesthetics and depolarizing relaxants. The estimated incidence of MH is between 1:10,000 and 1:250,000 anesthetic procedures. In Poland, due to lack of reporting, the incidence of MH is unknown. Dantrolene is imported as a life-saving drug (target import) and temporally authorized for sale. The aim of the study was to evaluate the prevalence of malignant hyperthermia in Poland and to assess the accessibility to dantrolene in Poland. A questionnaire was conducted among the chiefs of anesthesia and intensive care units in Poland. During the years 2014 to 2019, 10 episodes of MH have been reported in 238 surveyed polish anesthesia departments. The estimated prevalence is 1:350,000. Eight patients survived the MH crisis. Dantrolene is stocked in 48 (20%) anesthesiology departments. Among the surveyed hospitals, only in 38 (16%) it is possible to administer dantrolene within 5 minutes of suspecting a MH reaction. Less than half units (44%) have an algorithm for the management of MH episode in the operating theaters. The results of the study revealed, that the prevalence of MH in Poland is lower than the prevalence reported in other countries. Access to dantrolene in Poland is limited.
恶性高热（MH）是一种危及生命的综合征，由吸入麻醉剂和去极化肌松药引起的突发性、无法控制的骨骼肌代谢亢进引起。MH 的估计发病率为每 10,000 至 250,000 例麻醉程序。在波兰，由于缺乏报告，MH 的发病率尚不清楚。丹曲林作为一种救命药物（目标进口）进口，并临时授权销售。本研究旨在评估波兰恶性高热的流行情况，并评估波兰获得丹曲林的情况。对波兰麻醉和重症监护病房主任进行了问卷调查。在 2014 年至 2019 年期间，在 238 个接受调查的波兰麻醉部门报告了 10 例 MH 病例。估计发病率为 1:350,000。8 名患者在 MH 危机中幸存。丹曲林库存于 48 个（20%）麻醉科。在所调查的医院中，只有 38 家（16%）能够在怀疑 MH 反应后 5 分钟内给予丹曲林。不到一半的单位（44%）在手术室中具有 MH 发作的管理算法。研究结果表明，波兰的 MH 发病率低于其他国家报告的发病率。波兰获得丹曲林的机会有限。
